• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Myomo Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    7/15/24 4:05:34 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email
    8-K
    false 0001369290 0001369290 2024-07-11 2024-07-11

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 11, 2024

     

     

    Myomo, Inc.

    (Exact Name of Company as Specified in Charter)

     

     

     

    Delaware   001-38109   47-0944526

    (State or other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    137 Portland St., 4th Floor  
    Boston, MA   02114
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (617) 996-9058

    Not applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   MYO   NYSE American

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.01 Entry into a Material Definitive Agreement.

    On July 11, 2024 (the “Effective Date”), Myomo, Inc. (the “Company”), entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Bank”).

    The Loan Agreement provides for a revolving line of credit whereby the Company may borrow up to $4,000,000 (the “Revolving Line”), which Revolving Line may be increased to $5,500,000 at the Bank’s sole discretion upon the occurrence of certain events. Amounts advanced by the Bank are based on 80% of “eligible accounts”, which includes all receivables in the United States, reduced by aged amounts and customers and insurance payers with concentrations in excess of defined limits, among other deductions. The outstanding principal amount of any advance shall accrue interest at a floating rate per annum equal to the greater of (i) 8.50% and (ii) the “prime rate” as published in The Wall Street Journal for the relevant period plus one-half percent (0.50%). The Revolving Line is secured on a first priority basis by all of Company’s assets other than intellectual property and certain customary exceptions. Any newly formed or acquired subsidiary of the Company or any guarantor under the Loan Agreement, will either join the Loan Agreement as a co-borrower or become a guarantor under the Loan Agreement, as determined by the Bank in its sole discretion. The Company intends to use the Revolving Line for working capital and general business purposes.

    The Revolving Line terminates, and any outstanding principal amount of all advances made thereunder, and any accrued and unpaid interest thereon, become immediately due and payable on the two year anniversary of the Effective Date.

    The Company must also pay Bank (i) a commitment fee of $20,000, (ii) an “Anniversary Fee” of 0.50% of the Revolving Line and (iii) an “Unused Revolving Line Facility Fee” of 0.50% per annum of the average unused portion of the Revolving Line. In addition, upon termination of the Loan Agreement or the Revolving Line prior to the two year anniversary of the Effective Date, the Company must pay a termination fee of 1.00% of the Revolving Line, subject to certain exceptions.

    The Loan Agreement contains representations, warranties, and negative and affirmative covenants customary for transactions of this type. These include covenants limiting the ability of the Company, and any of their subsidiaries, subject to certain exceptions and baskets, to, among other things, (i) incur indebtedness, (ii) incur liens on their assets, (iii) enter into any merger or consolidation with, or acquire all or substantially all of the equity or property of, another person, (iv) dispose of any of their business or property, (v) make or permit any payment on subordinated debt, or (vi) pay any dividend, make any other distribution, or redeem any equity.

    The Loan Agreement contains customary events of default and also provides that an event of default includes any default resulting in a right by third parties to accelerate maturity of indebtedness in excess of $100,000. If any event of default occurs and is not cured within applicable grace periods set forth in the Loan Agreement or waived, all loans and other obligations could become due and immediately payable and the facility could be terminated. In addition, the Company may be required to deposit cash with the Bank in an amount equal to 105% of any undrawn letters of credit denominated in U.S. Dollars or 110% of any undrawn letters of credit denominated in a foreign currency.

    The foregoing summary of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the copy of the Loan Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

    The representations, warranties and covenants contained in the Loan Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Loan Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Loan Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Loan Agreement, and not to


    provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the Securities and Exchange Commission.

    Item 2.03 Creation of a Direct Financial Obligation.

    The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Loan Agreement is incorporated herein by reference into this Item 2.03.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number
      

    Description

    10.1    Loan and Security Agreement, dated July 11, 2024, between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        MYOMO, INC.
    Date: July 15, 2024     By:  

    /s/ David A. Henry

          Name: David A. Henry
          Title: Chief Financial Officer
    Get the next $MYO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    SEC Filings

    View All

    SEC Form S-8 filed by Myomo Inc.

    S-8 - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:49:09 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Myomo Inc.

    10-K - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:16:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:10:25 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo and Elevance Health Agree to Contract for Multi-State Network Participation

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45 million medical members will bring Myomo's total number of covered lives under commercial insurance plans to over 80 million. These a

    3/9/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Crowley Thomas Aloysius Jr. bought $3,233 worth of shares (4,385 units at $0.74), increasing direct ownership by 6% to 75,748 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/21/25 7:22:22 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $57,500 worth of shares (50,000 units at $1.15), increasing direct ownership by 12% to 474,420 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/26/25 8:10:16 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gudonis Paul R was granted 11,637 shares, increasing direct ownership by 0.93% to 1,260,650 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    1/14/26 4:20:20 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Chief Financial Officer Henry David A was granted 8,727 shares, increasing direct ownership by 2% to 436,627 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    1/14/26 4:19:07 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Myomo with a new price target

    Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    7/31/24 7:20:07 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Lake Street initiated coverage on Myomo with a new price target

    Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    5/20/24 9:00:38 AM ET
    $MYO
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Myomo with a new price target

    H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

    12/15/23 8:26:14 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Financials

    Live finance-specific insights

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Reports Third Quarter 2025 Financial and Operating Results

    Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. "Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ("O&P") revenues at record levels. Revenue increased while operating expenses decrease

    11/10/25 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Myomo Appoints Heather Getz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

    3/28/24 4:05:00 PM ET
    $BFLY
    $MYO
    Medical Electronics
    Health Care
    Industrial Specialties

    Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

    1/30/23 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    10/18/24 2:21:35 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/12/24 10:35:49 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/11/24 6:02:07 PM ET
    $MYO
    Industrial Specialties
    Health Care